Advanced Solid Tumours Clinical Trial
— AZD0424Official title:
A Cancer Research UK Phase I Study to Determine the Maximum Tolerated Dose of the Oral Src/Abl Inhibitor AZD0424, and to Identify Tolerable and Effective AZD0424 Combination Regimens for the Treatment of Advanced Solid Tumours
Verified date | July 2016 |
Source | Cancer Research UK |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the maximum tolerated dose of the oral Src/Abl inhibitor AZD0424, and to find tolerable and effective AZD0424 combination regimens for the treatment of advanced solid tumours
Status | Terminated |
Enrollment | 43 |
Est. completion date | May 2016 |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically proven solid tumour, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient or for whom there is the prospect of clinical benefit - Life expectancy of at least 12 weeks - World Health Organisation (WHO) performance status of 0-2 - Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week (Day -7 to Day 1) before the patient receives AZD0424 - Haemoglobin (Hb) = 9.0 g/dL - Absolute neutrophil count (ANC) = 1.5 x 109/L - Platelet count = 100 x 109/L - Serum bilirubin = 1.5 x upper limit of normal (ULN) - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x (ULN) Either: Calculated creatinine clearance = 50 mL/min Or Or Isotope Clearance measurement = 50 mL/min (uncorrected) - 18 years or over - Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up - MTD Expansion cohorts only: A tumour which is safely accessible for biopsy (single and combination) Exclusion Criteria: - Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C and four weeks for investigational medicinal products) before treatment. - Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator and the DDO should not exclude the patient. - Symptomatic brain metastases (if brain metastases are present they must have been stable for > 3 months). - Patients with evidence of interstitial lung disease (bilateral, diffuse, parenchymal lung disease). - Patients with a peanut allergy will be excluded. - Ability to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrollment and agree to use two highly effective forms of contraception as detailed in the protocol are considered eligible. - Male patients with partners of child-bearing potential (unless they agree to take measures not to father children by using one form of highly effective contraception as detailed in the protocol). Men with pregnant or lactating partners should be advised to use barrier method contraception (for example, condom plus spermicidal gel) to prevent exposure to the foetus or neonate. - Major thoracic or abdominal surgery from which the patient has not yet recovered. - At high medical risk because of non-malignant systemic disease including active uncontrolled infection. - Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV). - Resting ECG with measurable QTc interval of >480 msec (mean value and manually verified) of at least 3 time points within a 24 hour period. - Concurrent hypotension defined as a baseline supine blood pressure (BP) systolic < 90 mmHg. - Concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA]), prior history of cardiac ischaemia or prior history of cardiac arrhythmia within 6 months. Coronary angioplasty or stenting in the previous 12 months. - Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase Ia/Ib study of AZD0424 single agent and in combination. Participation in an observational, counseling or psychological trial would be acceptable. - Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Belfast City Hospital | Belfast | |
United Kingdom | Edinburgh Cancer Centre - Western General Hospital | Edinburgh | |
United Kingdom | Oxford University Hospitals NHS Trust | Oxford |
Lead Sponsor | Collaborator |
---|---|
Cancer Research UK |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Establishing the Maximum Tolerated Dose (MTD) of AZD0424 alone and in combination | |||
Primary | Determining the causality and duration of adverse events observed during the study according to NCI CTCAE Version 4.02 | |||
Secondary | Determining the correlation between PK studies and toxicity and/or efficacy. | |||
Secondary | Measurement of urinary and serum N terminal Telopeptide (NTx) and serum C-terminal peptide (CTx) levels before the first AZD0424 administration and then following first AZD0424 administration, to evaluate bone turnover | |||
Secondary | Measurement of the following biomarkers in tumour tissue before and after the first AZD0424 administration: p-Src, MKI67 (Ki-67), p-PAX, p-CRKL, p-FAK. | |||
Secondary | Evaluate responses (stable disease (SD), partial response (PR) or complete response (CR)) in any of the patients as determined by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05514132 -
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
|
Phase 1 | |
Terminated |
NCT04949425 -
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
|
Phase 1 | |
Not yet recruiting |
NCT05537051 -
A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT02579226 -
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01058538 -
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT02588105 -
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT03852823 -
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
|
Phase 1 | |
Not yet recruiting |
NCT06380816 -
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01585701 -
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor
|
Phase 1 | |
Completed |
NCT03101839 -
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT03150368 -
Extended Use of ModraDoc006/r
|
Phase 1 | |
Active, not recruiting |
NCT02389842 -
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib
|
Phase 1 | |
Terminated |
NCT01581060 -
Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
|
Phase 1/Phase 2 | |
Terminated |
NCT04959266 -
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
|
Phase 1 | |
Completed |
NCT04462952 -
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
|
Phase 1 | |
Active, not recruiting |
NCT03518606 -
Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT02430311 -
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
|
Phase 1 | |
Terminated |
NCT01859351 -
Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
|
Phase 1 | |
Completed |
NCT01163903 -
Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
|
Phase 1 | |
Recruiting |
NCT05804526 -
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
|
Phase 1/Phase 2 |